# A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS

> **NCT00627003** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 43 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** Cabergoline
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00627003
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2003-05
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2011-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00627003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00627003, "A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00627003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*